#

Pharmaceutical Companies

: 119
Ilya Yasny: It is easy to lose a lot of money on investments in biotech companies
Review·
Ilya Yasny: "It is easy to lose a lot of money on investments in biotech companies"
Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?
News·
Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
Small Caps·
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?
News·
The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?
Chinas biotech stocks post worst collapse in 5 months due to possible U.S. restrictions
News·
China's biotech stocks post worst collapse in 5 months due to possible U.S. restrictions
Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?
News·
Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?
Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug
Small Caps·
Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug
Wall Streets only bearish on Eli Lilly stock has changed its mind
News·
Wall Street's only bearish on Eli Lilly stock has changed its mind
Eli Lillys weight loss pill has passed one of the key phases of testing. Shares rose
News·
Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
News·
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
Novo Nordisk shares rise after approval of Wegovy to treat liver disease
News·
Novo Nordisk shares rise after approval of Wegovy to treat liver disease
Highlights of the week: Trump and duties, Palantir breaks records, OpenAI catches up with SpaceX
Review·
Highlights of the week: Trump and duties, Palantir breaks records, OpenAI catches up with SpaceX
Load more